Gates Foundation Strategic Investment Fund Logo
Share this page:

Press Release: Innovative partnership reduces cost of Bayer’s long-acting reversible contraceptive implant by more than 50 percent

Bill & Melinda Gates Foundation

February 27, 2013

An unprecedented group of public and private sector partners has finalized an agreement that will make Jadelle®, an effective, long-acting, reversible contraceptive implant, available to more than 27 million women in the world’s poorest countries at a more than 50 percent price reduction over the next six years.

The Jadelle Access Program – developed and supported through a partnership between Bayer HealthCare AG, the Bill & Melinda Gates Foundation, the Clinton Health Access Initiative (CHAI), the Governments of Norway, the United Kingdomthe United States and Sweden, and the Children’s Investment Fund Foundation (CIFF) and the United Nations Population Fund (UNFPA) – builds on momentum generated at the July 2012 London Summit on Family Planning, where global leaders pledged to provide an additional 120 million women in developing countries with contraceptive access by 2020. It also supports the recommendations of the UN Commission on Life-Saving Commodities by helping to shape global markets in order to increase the availability of quality, life-saving commodities at an optimal price and volume.

Read the full text here.